Physician profile
Barry Ceverha
NPI 1972576486
$944.67
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $423 · 2021: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $163.15 | 2019-2021 | |
| Allergan, INC. | $135.08 | 2020 | |
| Integra Lifesciences Corporation | $121.95 | 2019 | |
| Csl Behring | $92.67 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $72.51 | 2020 | |
| Medtronic USA, INC. | $59.74 | 2019 | |
| Neurocrine Biosciences, INC. | $55.90 | 2020 | |
| Abbott Laboratories | $54.22 | 2019 | |
| Abbvie INC. | $31.94 | 2021 | |
| Amgen INC. | $26.57 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.89 | 2021 | |
| Mallinckrodt Enterprises LLC | $22.27 | 2019 | |
| Horizon Therapeutics Plc | $20.69 | 2021 | |
| Biogen, INC. | $19.42 | 2021 | |
| Medtronic Vascular, INC. | $16.73 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $15.56 | 2019 | |
| Lemaitre Vascular, INC. | $12.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Ceverha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.